+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

W

Actively Recruiting

Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.

Age: 10Years - 17YearsAll GendersPhase 3
81 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.

Age: 5Years - 11YearsAll GendersPhase 3
147 locations
E

Actively Recruiting

Researchers are evaluating lumateperone in a study involving children and teenagers aged 5 to 17 years who have irritability linked to Autism Spectrum Disorder ASD. This is a randomized, double-blind, placebo-controlled trial aimed at assessing the safety and effectiveness of lumateperone in this pediatric population. Diagnosis is confirmed using DSM-5-TR criteria and the K-SADS-PL assessment tool. Participants will be randomly assigned to one of three groups to receive either a high dose of lumateperone 42 mg, a low dose of lumateperone 21 mg, or a placebo. The treatment is taken orally once daily during a 6-week double-blind period. The study includes an initial screening phase lasting up to 14 days, and a safety follow-up visit occurs about one week after the last dose. During the study, participants will attend visits for screening, treatment, and safety follow-up. Researchers will evaluate irritability using the Aberrant Behavior Checklist - Irritability subscale at 6 weeks, along with the Clinical Global Impression-Severity scale. Safety monitoring will be conducted throughout, and total participation spans screening, 6 weeks of treatment, and a 1-week follow-up period.

Age: 5Years - 17YearsAll GendersPhase 3
41 locations
S

Actively Recruiting

Measuring the pressure inside the skull, known as intracranial pressure ICP, is important for treating serious neurological conditions. Currently, measuring ICP requires an invasive procedure where a monitor is placed inside the skull. Researchers are evaluating a new non-invasive device from Brain4Care that uses a tiny pin placed on the head to detect small skull movements with each heartbeat, producing a waveform similar to invasive ICP measurements. This study aims to understand how this non-invasive ICP monitor waveform changes during standard treatments that lower ICP. The study involves adult patients over 18 who are undergoing brain surgery requiring hyperosmolar agents, those receiving lumbar punctures in neuro-oncology or neurosurgery clinics, or patients with ventriculo-peritoneal shunts needing adjustments. The non-invasive Brain4Care device will be used to monitor ICP waveforms as patients receive their usual care. The device measures skull pulsations to generate a waveform analyzed by factors like the P2P1 ratio and time to peak, which relate to intracranial pressure dynamics. Participants will be observed during their routine clinical care with the non-invasive device monitoring their intracranial pressure waveforms. Researchers will track changes in the P2P1 ratio from enrollment through completion, which may last up to about 100 weeks. The study includes assessments during various ICP-lowering procedures, and participants must be able to consent for themselves. No experimental treatments will be given, and the focus is on gathering data to better understand the devices clinical usefulness.

Age: 18Years +All Genders
1 location
O

Actively Recruiting

This research aims to evaluate an online relationship program designed for couples where one or both partners are in recovery from substance misuse. The study focuses on strengthening romantic relationships and improving individual well-being by addressing common issues like relationship conflict and distress that can interfere with substance use disorder SUD recovery. The program is based on Integrative Behavioral Couple Therapy IBCT, adapted for digital delivery and tailored specifically to the challenges faced by couples in recovery. Couples in this study will participate in approximately 8 to 10 hours of online content delivered over 5 to 8 weeks. The program includes sections called Observe, Understand, and Respond, which guide partners through identifying relationship problems, understanding core issues, and developing strategies to improve communication and reduce stress. The content features videos, audio, graphics, interactive feedback, and examples of diverse couples. Couples also receive up to five 20-minute coaching calls conducted via phone or Zoom to support their progress throughout the program. Participants will complete online surveys before starting and after finishing the program to assess changes in relationship satisfaction, conflict, emotional trust, and recovery-related factors. Researchers will monitor progress during the approximately 8-week intervention period. The study provides 200 per couple for completing surveys. Throughout participation, couples will have access to digital content and scheduled coaching, aiming to support both relationship and individual recovery. The total involvement includes program completion and follow-up assessments.

Age: 18Years +All GendersPhase Not Applicable
5 locations
O

Actively Recruiting

Researchers are evaluating the safety and tolerability of lumateperone in children and adolescents diagnosed with schizophrenia, bipolar disorder, or autism spectrum disorder. This open-label, multicenter study lasts 26 weeks and aims to better understand how this medication affects pediatric patients with these conditions. The study includes patients who are either new to treatment or rolling over from previous related studies. Participants will receive lumateperone once daily in capsule or orally disintegrating tablet form, with doses ranging from 5 mg to 42 mg based on their age and condition. The trial begins with a screening period up to 2 weeks to confirm eligibility, followed by a 26-week treatment phase where all participants receive open-label lumateperone. After treatment, there is a 2-week safety follow-up visit approximately 2 weeks after the last dose. Throughout the study, participants will attend clinic visits for monitoring and assessments. Researchers will collect safety data, including tracking common adverse events up to six months. Patients must be outpatients expected to remain so during the study. Safety follow-up helps ensure ongoing monitoring after treatment ends, with the entire participation lasting about 28 weeks including screening and follow-up.

Age: 5Years - 17YearsAll GendersPhase 3
65 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of MANP, a modified atrial natriuretic peptide, for people with difficult to control or resistant hypertension. This Phase 2, randomized, double-blind, placebo-controlled study aims to see if daily subcutaneous injections of MANP can reduce daytime systolic blood pressure measured by 24-hour ambulatory monitoring in patients taking three or more blood pressure medications. Participants will be randomly assigned to receive either MANP or a placebo once daily for 42 days. The study includes a dose titration process to find the appropriate dose. The placebo is a matched vehicle without the active drug. This trial is conducted at multiple centers and uses a quadruple-blind design to ensure unbiased results. During the study, participants will have their blood pressure monitored regularly, including 24-hour ambulatory blood pressure monitoring and clinic sitting blood pressure readings. Safety will be assessed by tracking adverse events and serious adverse events for up to 10 weeks, including 4 weeks after treatment ends. Blood samples will be taken to study drug levels and immune responses. The total participation time is about 10 weeks with regular visits for monitoring and assessments.

Age: 18Years - 80YearsAll GendersPhase 2
23 locations